The Effect of GLP-1 Receptor Activation on Central Reward and Satiety in Obesity and Diabetes
Status:
Completed
Trial end date:
2013-10-01
Target enrollment:
Participant gender:
Summary
Glucagon-like peptide 1 (GLP-1) based therapies, such as exenatide, are already successfully
employed in the treatment of Type 2 Diabetes (T2DM). Exenatide improves glycemic control and
is associated with reduced food intake and body weight. The investigators hypothesize that it
affects central reward and satiety circuits and that this may contribute to the weight loss.